KZIA · Kazia Therapeutics Limited ADR
United States · RS rating 15 · As of 2026-10-14
| Price | 6.79 USD |
|---|---|
| 1-day change | -15.6% |
| RS rating (overall / 1M / 3M / 12M) | 15 / 5 / 5 / 45 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 19 / 25 / 10 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +59.8% |
| Market cap (USD) | $135.1M |